COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers

London, United Kingdom April 20, 2022

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today today partnered with One Mind, a California-based nonprofit mental health research leader, to sponsor three “2022 One Mind – COMPASS Rising Stars Awards.”

The One Mind Rising Star Awards are given annually to promising early career researchers who are pursuing research that has the potential to significantly advance the understanding and treatment of mental illness and improve patient outcomes. A Request Apps was released by One Mind today and up to three winners will be selected by One Mind’s Scientific Advisory Board through a competitive process. The winners, to be announced in September 2022, will each receive a COMPASS-sponsored $300,000 research grant over three years. They will also be able to participate in certain leadership and entrepreneurial development opportunities through the One Mind Rising Star Development Program offered by One Mind.

Brandon Staglin, President of One Mind, said, “Since 2005, One Mind has awarded 40 Rising Star Awards to some of the best and brightest early career brain scientists. We want to catalyze innovation and encourage collaboration and data sharing so that we can have an impact on some truly devastating diseases. We are thrilled to work with COMPASS, whose mission and values, along with a focus on patient care, align so well with everything we do at One Mind.

This partnership with One Mind is in line with COMPASS’s commitment to identify and support world-class talent in the field of neuroscience and mental health research. COMPASS is one of the founders of the British Neuroscience Association’s inaugural Scholars programme, which supports scientists from underrepresented ethnic groups. COMPASS also funds several PhD students in neuroscience at leading institutions in the United States and Europe.

Ekaterina Malievskaia MD, Chief Innovation Officer and Co-Founder of COMPASS Pathways, said, “Many of us at COMPASS know firsthand how difficult it can be to live with a mental health disorder. We have long admired the work of One Mind. pushing the boundaries of brain health research and supporting high-risk innovation. We are excited about this collaboration and look forward to supporting the next generation of brain scientists.


About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our goal is to improve the lives of those who suffer from mental health problems and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated Breakthrough Therapy by the U.S. Food and Drug Administration (FDA) for Treatment Resistant Depression (TRD), and we have completed a Phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites in Europe and North America. . This was the largest randomized, controlled, double-blind clinical trial of psilocybin therapy ever conducted, and our primary data showed a statistically significant (p

Availability of other COMPASS Pathways information

Investors and others should note that we communicate with our investors and the public through our website (, our investor relations website ( and social media (LinkedIn), including, but not limited to, investor presentations and investor information sheets, filings with the United States Securities and Exchange Commission, press releases, public conference calls and webcasts. The information we post on these channels and websites could be considered material information. Accordingly, we encourage investors, the media and others interested in us to regularly review the information posted on these channels, including the Investor Relations website. This list of channels may be updated from time to time on our Investor Relations website and may include additional social media channels. The content of our website or these channels, or any other website accessible from our website or these channels, should not be taken as incorporated by reference in any filing under the Securities Act of 1933.

Forward-looking statement s

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements may be identified by words such as “may”, “could”, “will”, “could”, “should”, “should”, “expect”, “has intention to”, “plan”, “goal”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “in progress”, or the negative form of these terms or other comparable terms, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements regarding, among other things, the safety or effectiveness of COMP360 psilocybin therapy as a treatment for depression, COMPASS’s strategy and business objectives, including its ability to launch and commercialize products, COMPASS’s ability to continue to advance its research or develop plans to bring its product candidates to patients, including COMP360, and COMPASS’s expectations regarding the benefits of its psilocybin therapy. The forward-looking statements contained in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond within the control of COMPASS and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by such forward-looking statements.

These risks, uncertainties and other factors include, among others: preclinical research and clinical development are long and uncertain, and therefore our preclinical studies and clinical trials may be delayed or interrupted, or may never advance to or into the clinic; and the risks and uncertainties described under “Risk Factors” in COMPASS’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on February 24, 2022 and in subsequent filings. by COMPASS with the SEC, which are available on the SEC’s website at Except as required by law, COMPASS disclaims any intention or responsibility to update or revise any forward-looking statements contained in this press release as a result of new information, future developments or otherwise. These forward-looking statements are based on COMPASS’s current expectations and speak only as of the date hereof.

About one mind

One Mind is a leading nonprofit mental health organization that heals lives through brain research, ranging from science to service to society. By bringing together the best minds in brain science and advocacy around our collective vision “Accelerating Brain Health for All”, One Mind delivers a three-pronged program strategy of accelerating discovery, scaling implementation and to transform the societal culture. Together, we are creating a world where everyone facing brain health issues can lead healthy and productive lives.


Media: Tracy Cheung, [email protected], +44 7966 309024
Investors: Stephen Schultz, [email protected], +1 401 290 7324

main logo

Comments are closed.